Value of cytokeratin-19, Hector Battifora mesothelial-1 and galectin-3 immunostaining in the diagnosis of thyroid neoplasms
暂无分享,去创建一个
N. Hulikal | A. Chowhan | A. Sachan | R. Nandyala | Rajasekhar Sanuvada | Phaneendra V Bobbidi | M. Yootla
[1] V. Satyanarayana,et al. Profile Of Thyroid Neoplasms With Special Focus On Interesting Cases: A Hospital Based 12 Year Longitudinal Study , 2013 .
[2] J. Gardovskis,et al. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. , 2012, Medicina.
[3] Chang-Sheng Li,et al. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China , 2011, Diagnostic pathology.
[4] A. Faur,et al. THE VALUE OF CK19, KI-67 AND P53 EXPRESSION IN THE DIAGNOSIS OF THYROID FOLLICULAR NEOPLASMS , 2011 .
[5] S. Seçkın,et al. Expression of CK-19, cErbB2, galectin-3, and p53 in papillary thyroid carcinomas , 2010, Turkish Journal of Medical Sciences.
[6] S. Kwak,et al. Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27kip1 in the Differential Diagnosis of Thyroid Nodules , 2007, Journal of Korean medical science.
[7] S. Mukhopadhyay,et al. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: utility of HBME1 combined with CK19 immunostaining , 2006, Modern Pathology.
[8] Yao-Tseng Chen,et al. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. , 2006, American journal of clinical pathology.
[9] K. Young,et al. Usefulness of Galectin-3, Cytokeratin 19, p53, and Ki-67 for the Differential Diagnosis of Thyroid Tumors , 2006 .
[10] K. Metze,et al. Usefulness of HBME‐1, cytokeratin 19 and galectin‐3 immunostaining in the diagnosis of thyroid malignancy , 2005, Histopathology.
[11] M. Papotti,et al. Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential , 2005, Modern Pathology.
[12] H. Nagaraja,et al. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors , 2005, Modern Pathology.
[13] L. Truong,et al. Cytokeratin 19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. , 2003, Archives of pathology & laboratory medicine.
[14] M. Beesley,et al. Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules , 2002, Histopathology.
[15] C. Cheung,et al. Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma , 2001, Modern Pathology.
[16] L. Grimelius,et al. Cytokeratin 19 expression in papillary thyroid carcinoma , 1999 .
[17] T. Jo,et al. Thyroid cancers in Ibadan, Nigeria. , 1995 .
[18] J. Ogunbiyi,et al. Thyroid cancers in Ibadan, Nigeria. , 1995, East African medical journal.
[19] A. R. Khan,et al. Pattern of cancer at Asir Central Hospital, Abha, Saudi Arabia. , 1991, Annals of Saudi medicine.
[20] G. Ejeckam,et al. Histological pattern of thyroid diseases in Enugu, Nigeria. , 1983, East African Medical Journal.
[21] W. Gitau. An analysis of thyroid diseases seen at Kenyatta National Hospital. , 1975, East African medical journal.
[22] B. M. Black,et al. Occult papillary carcinoma of the thyroid gland: a study of 140 cases observed in a 30-year period. , 1960, The Journal of clinical endocrinology and metabolism.